降低ATG13的ULK1/2抑制剂有效向KRAS突变癌症
bioRxiv : the preprint server for biology
|November 24, 2025
概括
一种新型药物SBP-1750针对KRAS突变癌症中的自相关基因 (ATG) 蛋白. 这种药物抑制ULK1激酶活性,降解关键ATG蛋白,并减少瘤生长,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- KRAS突变是肺癌和胰腺癌的关键驱动因素.
- 自,由ULK激酶启动,支持瘤生长,是KRAS突变癌症的目标.
- ULK1和ATG13是自启动复合体的重要组成部分.
研究的目的:
- 为了识别和评估ULK抑制剂针对KRAS突变癌症的自.
- 在临床前癌症模型中评估新型ULK抑制剂SBP-1750的疗效.
主要方法:
- 在KRAS突变肺癌细胞中开发了一种使用HiBiT标记ATG13的高通量选试验.
- 对ULK激酶抑制和ATG13降解进行了SBP-1750的测试.
- 评估了SBP-1750在 ортотоп胰腺癌模型中的抗瘤疗效,并分析了免疫细胞透.
主要成果:
- SBP-1750强烈抑制ULK活性并诱导ATG13降解,导致KRAS突变癌细胞死亡.
- 在胰腺癌模型中,口服SBP-1750显著降低了瘤生长.
- SBP-1750治疗增加了瘤中CD4+和CD8+T细胞的透,增强了抗瘤免疫力.
结论:
- SBP-1750是一种有前途的新型治疗剂,针对KRAS突变癌症的自途径.
- SBP-1750显示出抗瘤活性和免疫调节作用.
- 进一步开发SBP-1750作为针对ATG的癌症治疗是有必要的.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Small GTPases - Ras and Rho
5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.2K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K


